2023
DOI: 10.7759/cureus.40474
|View full text |Cite
|
Sign up to set email alerts
|

Safety and Efficacy of Ondansetron and Simvastatin as Potential Adjunctive Treatment for Patients With Schizophrenia: A Systematic Review of Randomized Controlled Trials

Abstract: In a generation where advancements in research and understanding have led to remarkable achievements in medicine, it is still unfathomable that, after more than a century, the cause of schizophrenia is still a mystery. While antipsychotics, without a doubt, have brought on an exemplary revolution in the way psychiatric disorders are now treated, there are still imperative deficits that need to be addressed to ultimately enable individuals with schizophrenia to function normally in society. However, without a d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 32 publications
0
3
0
Order By: Relevance
“…Two other studies found that 5-HT receptor antagonists, including sarpogrelate and tropisetron, could decrease the production of pro-inflammatory cytokines in shock models ( Nishiyama, 2009 ; Setoguchi et al, 2011 ). In addition, ondansetron has been used to control symptoms of neuropsychiatric diseases, including obsessive compulsive disorder, through decreasing the dopaminergic activity and the release of serotonin, norepinephrine, and acetylcholine, which also play an important role in the pathophysiological process of TBI ( Eissazade et al, 2023 ; Khan et al, 2023 ). Therefore, we reasonably hypothesize that ondansetron could improve the prognosis of TBI by regulating coagulation, inflammation, and immune status and protecting the kidney and brain after an injury.…”
Section: Discussionmentioning
confidence: 99%
“…Two other studies found that 5-HT receptor antagonists, including sarpogrelate and tropisetron, could decrease the production of pro-inflammatory cytokines in shock models ( Nishiyama, 2009 ; Setoguchi et al, 2011 ). In addition, ondansetron has been used to control symptoms of neuropsychiatric diseases, including obsessive compulsive disorder, through decreasing the dopaminergic activity and the release of serotonin, norepinephrine, and acetylcholine, which also play an important role in the pathophysiological process of TBI ( Eissazade et al, 2023 ; Khan et al, 2023 ). Therefore, we reasonably hypothesize that ondansetron could improve the prognosis of TBI by regulating coagulation, inflammation, and immune status and protecting the kidney and brain after an injury.…”
Section: Discussionmentioning
confidence: 99%
“…No significant difference were found for CRP > 1 mg/L, CRP >3.9 mg/L, CRP > 4 mg/L, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17a, TNF-α and IFN-γ, CD4+, CD8+, CD19+, and sIL-2R [ 48 , 60 , 63 , 64 , 71 , 73 , 74 , 80 ]. Several previous meta-analyses and systematic reviews on anti-inflammatory add-on drugs to antipsychotics exist, but none have investigated baseline immunological biomarkers and the prediction of treatment response [ 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 49 , 50 , 52 , 53 , 54 , 55 , 56 , 94 ].…”
Section: Discussionmentioning
confidence: 99%
“…A recent meta-analysis showed that drugs possessing either primary or pleiotropic anti-inflammatory properties, as an add-on to the antipsychotic treatment of psychotic disorders, improve the negative and positive symptoms and slow cognitive decline compared to placebos [ 38 ]. In addition, several previous meta-analyses on add-on drugs with either primary or pleiotropic anti-inflammatory properties have been performed, but none of the previous meta-analyses investigated baseline immune biomarkers and treatment effects [ 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 ].…”
Section: Introductionmentioning
confidence: 99%